Latest Darbepoetin alfa Stories
THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for NplateÂ® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Study highlights: - Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke. - This first large, randomized, placebo-controlled trial finds drug raises hemoglobin levels and reverses anemia but does not improve patient cardiovascular outcomes. - Treatment with darbepoetin alfa in patients with type 2 diabetes, chronic kidney disease and moderate anemia doubled the risk of stroke compared to...
Use of erythropoiesis-stimulating agents is associated with an increased risk of venous thromboembolism.
New research has increased concerns over the use of anemia medicines, since the discovery that the drug Aranesp and others have doubled the chance of stroke in diabetes patients and those with continual kidney problems.
THOUSAND OAKS, Calif., Oct.
WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ -- Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).
THOUSAND OAKS, Calif., Aug.
New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present new data from the Company's oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting...
HORSHAM, Pa., May 13 /PRNewswire/ -- Data from a study of managed-care cancer patients receiving chemotherapy and newly treated with erythropoiesis-stimulating agents (ESAs) found that the cumulative ESA cost with Epoetin alfa (EPO) was 29 percent lower than treatment with darbepoetin alfa (DARB).
The use of drugs to encourage red blood cell formation (erythropoiesis-stimulating agents) in cancer patients with anemia increases the risk of death and serious adverse events such as blood clots, found a new study in CMAJ.
- An armed gangster.